Surrozen, Inc./DE
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
SRZN$32.64+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(63,564) | $(43,042) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 1,442 | 1,911 |
| Stock-based compensation | 4,114 | 4,372 |
| Non-cash operating lease expense | 1,522 | 1,273 |
| Amortization of discount on marketable securities, net | — | (732) |
| Transaction costs allocated to pre-funded warrants and warrants in connection with the Private Placement | 1,507 | — |
| Loss on issuance of common stock, pre-funded warrants and warrants | 20,397 | — |
| Non-cash impairment of long-lived assets | — | 169 |
| Change in fair value of warrant liabilities | 17,830 | (211) |
| Warrant asset recognized in connection with research service revenue | (153) | — |
| Loss (gain) on foreign currency remeasurement | 113 | (174) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable - related party | (502) | — |
| Prepaid expenses and other current assets | 1,111 | 915 |
| Other assets | 71 | 62 |
| Accounts payable | (228) | (133) |
| Accrued and other liabilities | 1,056 | (2,550) |
| Operating lease liabilities | (2,344) | (2,223) |
| Net cash used in operating activities | (17,628) | (40,363) |
| Investing activities: | ||
| Purchases of property and equipment | (26) | (398) |
| Purchases of marketable securities | — | (28,044) |
| Proceeds from maturities of marketable securities | — | 80,165 |
| Net cash (used in) provided by investing activities | (26) | 51,723 |
| Financing activities: | ||
| Proceeds from issuance of common stock, pre-funded warrants and warrants in the Private Placement, net of transaction costs | 16,043 | — |
| Proceeds from issuance of common stock upon exercise of stock options | 39 | 3 |
| Proceeds from issuance of common stock upon employee stock plan purchases | 94 | 332 |
| Repurchase of early exercised stock options | — | (55) |
| Redemption of fractional shares due to reverse stock split | — | (4) |
| Net cash provided by financing activities | 16,176 | 276 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (1,478) | 11,636 |
| Cash, cash equivalents and restricted cash at beginning of year | 36,731 | 25,095 |
| Cash, cash equivalents and restricted cash at end of year | $35,253 | $36,731 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Increase in right-of-use assets and lease liabilities due to a lease modification | $7,434 | $— |
| Purchases of equipment included in accounts payable | $9 | $— |
| Vesting of early exercises of stock options | $2 | $32 |
The following table presents a reconciliation of the Company’s cash, cash equivalents and restricted cash in the Company’s consolidated balance sheets:
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash and cash equivalents | $34,565 | $36,043 |
| Restricted cash | 688 | 688 |
| Cash, cash equivalents and restricted cash | $35,253 | $36,731 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.